×
About 138 results

ALLMedicine™ Anaplastic Oligoastrocytoma Center

Research & Reviews  42 results

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anap...
https://clinicaltrials.gov/ct2/show/NCT02942264

Sep 28th, 2021 - Background: Zotiraciclib (TG02) is a pyrimidine-based multi-kinase inhibitor that has been shown to have inhibitory effects on cyclin-dependent kinases (CDKs), Janus Kinase 2 (JAK2) and Fm-like tyrosine kinase 3 (Flt3). It is orally administered a...

Oligodendroglioma Imaging
https://emedicine.medscape.com/article/342958-overview

Jul 16th, 2020 - Practice Essentials Oligodendroglioma is a well-differentiated, diffusely infiltrating tumor of adults that is typically located in the cerebral hemispheres and is predominantly composed of cells that morphologically resemble oligodendroglia. [1, ...

Oligodendroglioma Imaging
http://emedicine.medscape.com/article/342958-overview

Jul 16th, 2020 - Practice Essentials Oligodendroglioma is a well-differentiated, diffusely infiltrating tumor of adults that is typically located in the cerebral hemispheres and is predominantly composed of cells that morphologically resemble oligodendroglia. [1, ...

Oligodendroglioma Imaging
https://emedicine.medscape.com/article/342958-print

Jul 16th, 2020 - Oligodendroglioma is a well-differentiated, diffusely infiltrating tumor of adults that is typically located in the cerebral hemispheres and is predominantly composed of cells that morphologically resemble oligodendroglia.[1, 2] The hallmark molec...

Brain Cancer Staging
https://emedicine.medscape.com/article/2006770-overview

Oct 15th, 2019 - Grading of Brain Tumors The widely used tumor-node-metastasis (TNM) classification system was found to be inappropriate for brain tumors, as tumor size is less relevant than tumor histology and location, the brain has no lymphatics, and most of th...

see more →

Guidelines  1 results

SEOM clinical guidelines for anaplastic gliomas (2017).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785606
Clinical & Translational Oncology : Official Publication ... Balañá C, Alonso M et. al.

Oct 24th, 2017 - The SEOM/GEINO clinical guidelines provide recommendations for radiological, and molecular diagnosis, treatment and follow-up of adult patients with anaplastic gliomas (AG). We followed the 2016 WHO classification which specifies the major diagnos...

see more →

Clinicaltrials.gov  6 results

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anap...
https://clinicaltrials.gov/ct2/show/NCT02942264

Sep 28th, 2021 - Background: Zotiraciclib (TG02) is a pyrimidine-based multi-kinase inhibitor that has been shown to have inhibitory effects on cyclin-dependent kinases (CDKs), Janus Kinase 2 (JAK2) and Fm-like tyrosine kinase 3 (Flt3). It is orally administered a...

Study of Tissue and Blood Samples From Patients With High-Grade Glioma
https://clinicaltrials.gov/ct2/show/NCT01004887

Jan 17th, 2019 - OBJECTIVES: To evaluate the diagnostic and prognostic relevance of various molecular, cytogenetic, and other tumor markers in high-grade glioma in paraffin-embedded tissue collected from patients enrolled in the Mayo Clinic or North Central Cancer...

Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease Progression?
https://clinicaltrials.gov/ct2/show/NCT03068520

Mar 21st, 2017 - The multimodality approach for management of primary and secondary brain tumors includes surgery, radiotherapy and chemotherapy. Determination of an objective response to treatment relies on imaging findings (e.g. CT, MRI, PET).During the course o...

LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
https://clinicaltrials.gov/ct2/show/NCT00859222

Mar 14th, 2017 - Phase I Primary Objective • To determine the maximum tolerated dose (MTD) of LBH589 in combination with bevacizumab given at 10 mg/kg every 2 weeks in patients with recurrent glioblastoma (GBM), gliosarcoma, anaplastic astrocytoma, anaplastic olig...

Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial
https://clinicaltrials.gov/ct2/show/NCT01847235

Apr 26th, 2016 - Patient with relapsed or advanced anaplastic oligodendroglioma and anaplastic oligoastrocytoma will be enrolled. Enrolled patients will begin on temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle). Pat...

see more →

News  4 results

Toca 511 Shows Promise in High-Grade Glioma
https://www.onclive.com/view/toca-511-shows-promise-in-highgrade-glioma

Dec 20th, 2020 - Timothy Cloughesy, MD The gene for an anticancer drug was successfully transduced in high-grade gliomas, according to data from a phase I trial of Toca 511 presented at the 2016 Society for Neuro-Oncology Annual Meeting. Additionally, the median ...

5 Abstracts Offer Snapshot of Immunology Research
https://www.onclive.com/view/5-abstracts-offer-snapshot-of-immunology-research

Dec 5th, 2020 - The carcinoembryonic antigen (CEA) vaccinia has been researched for more than 20 years. Investigational Glioma Vaccine Results Promising A novel vaccine based on dendritic cells and peptides proved to be safe and capable of delivering an im...

Investigators Hope Glioma Trial of Eflornithine Will Clinch Approval
https://www.onclive.com/view/investigators-hope-glioma-trial-of-eflornithine-will-clinch-approval

Dec 5th, 2020 - Victor A. Levin, MD Eflornithine (α-Difluoromethylornithine) has been investigated for over 30 years as a potential neuro-oncology agent and shown activity against recurrent gliomas, but it has not gained approval as a therapy option for patients...

Novel Combo Explored for Rare Brain Tumor
https://www.onclive.com/view/novel-combo-explored-for-rare-brain-tumor

Dec 5th, 2020 - Victor A. Levin, MD Investigators are seeking to determine whether the combination of eflornithine (alphadifluoromethylornithine) with lomustine can improve survival for patients with recurrent anaplastic astrocytoma (AA). A rare form of brain tu...

see more →

Patient Education  2 results see all →